Signal regulatory proteins of the ␣ subtype (SIRP␣) are ubiquitous molecules of the immunoglobulin superfamily that negatively regulate protein tyrosine kinase receptor-dependent cell proliferation. Their intracytoplasmic domain contains four motifs that resemble immunoreceptor tyrosine-based inhibition motifs (ITIMs) and that, when tyrosyl-phosphorylated, recruit cytoplasmic SH2 domain-bearing protein tyrosine phosphatases (SHPs). ITIMs are borne by molecules that negatively regulate cell activation induced by receptors bearing immunoreceptor tyrosine-based activation motifs (ITAMs). Because SIRP␣ are coexpressed with ITAM-bearing receptors in hematopoietic cells, we investigated whether SIRP␣ could negatively regulate ITAM-dependent cell activation. We found SIRP␣ transcripts in human mast cells, and we show that a chimeric molecule having the transmembrane and intracytoplasmic domains of SIRP␣ could inhibit IgE-induced mediator secretion and cytokine synthesis by mast cells. Inhibition required that the SIRP␣ chimera was coaggregated with ITAM-bearing high affinity IgE receptors (Fc⑀RI). It was correlated with the tyrosyl phosphorylation of the SIRP␣ chimera and the recruitment of SHP-1 and SHP-2. The phosphorylation of Fc⑀RI ITAMs was decreased; the mobilization of intracellular Ca 2؉ and the influx of extracellular Ca 2؉ were reduced, and the activation of the mitogen-activated protein kinases Erk1 and Erk2 was abolished. SIRP␣ can therefore negatively regulate not only receptor tyrosine kinase-dependent cell proliferation but also ITAM-dependent cell activation.
Signal regulatory proteins of the ␣ subtype (SIRP␣) are ubiquitous molecules of the immunoglobulin superfamily that negatively regulate protein tyrosine kinase receptor-dependent cell proliferation. Their intracytoplasmic domain contains four motifs that resemble immunoreceptor tyrosine-based inhibition motifs (ITIMs) and that, when tyrosyl-phosphorylated, recruit cytoplasmic SH2 domain-bearing protein tyrosine phosphatases (SHPs). ITIMs are borne by molecules that negatively regulate cell activation induced by receptors bearing immunoreceptor tyrosine-based activation motifs (ITAMs). Because SIRP␣ are coexpressed with ITAM-bearing receptors in hematopoietic cells, we investigated whether SIRP␣ could negatively regulate ITAM-dependent cell activation. We found SIRP␣ transcripts in human mast cells, and we show that a chimeric molecule having the transmembrane and intracytoplasmic domains of SIRP␣ could inhibit IgE-induced mediator secretion and cytokine synthesis by mast cells. Inhibition required that the SIRP␣ chimera was coaggregated with ITAM-bearing high affinity IgE receptors (Fc⑀RI). It was correlated with the tyrosyl phosphorylation of the SIRP␣ chimera and the recruitment of SHP-1 and SHP-2. The phosphorylation of Fc⑀RI ITAMs was decreased; the mobilization of intracellular Ca 2؉ and the influx of extracellular Ca 2؉ were reduced, and the activation of the mitogen-activated protein kinases Erk1 and Erk2 was abolished. SIRP␣ can therefore negatively regulate not only receptor tyrosine kinase-dependent cell proliferation but also ITAM-dependent cell activation.
Signal regulatory proteins (SIRPs) 1 were described as phosphoproteins that coprecipitated with SH2 domain-bearing protein tyrosine phosphatases (SHPs) (1) (2) (3) . SIRP molecules were first identified as SHP substrate 1 (SHPS-1) (2) and brain immunoglobulin-like molecules with tyrosine-based activation motifs (BIT) (4) . When cloned, these molecules were found to be the members of a multigene family of at least 15 transmembrane immunoglobulin superfamily molecules named collectively SIRPs, in which two types, ␣ and ␤, were recognized, differing by the presence (in SIRP␣) or the absence (in SIRP␤) of an intracytoplasmic (IC) domain containing four tyrosinebased regulatory motifs (3) . A neuronal adhesion molecule, previously described as P84, was found to belong to the SIRP family, and the widely expressed integrin-associated protein CD47 was recently identified as a ligand of P84 (5) . Interestingly, SIRP␣ were shown to regulate negatively cell proliferation induced by growth factors via protein tyrosine kinase receptors (RTKs) and oncogene products. Little is known of the mechanism of inhibition by SIRP␣, except that negative regulation was correlated with the tyrosyl phosphorylation of SIRP␣ and the recruitment of SHP-2 (3, 6) . That SIRP␣ had inhibitory properties indicated that these molecules bear inhibition motifs rather than activation motifs. SHP-2-binding motifs found in SIRP␣ are indeed reminiscent of immunoreceptor tyrosine-based inhibition motifs (ITIMs). ITIMs are present in a large group of molecules (7) that negatively regulate cell activation induced by receptors bearing immunoreceptor tyrosine-based activation motifs (ITAMs) (8) . Negative regulation by ITIM-bearing molecules is correlated with the recruitment of SH2 domain-bearing phosphatases by phosphorylated ITIMs (9, 10) . Thus, killer cell inhibitory receptors (KIRs) inhibit cell-mediated cytotoxicity when they bind to major histocompatibility complex class I molecules on target cells (11) . Their IC domain contains two ITIMs that, when tyrosyl-phosphorylated, recruit SHP-1 and SHP-2 (12, 13) . Likewise, Fc␥RIIB, a family of low affinity receptors for IgG, negatively regulate cell activation via ITAM-bearing receptors when coaggregated with the latter by immune complexes (8) . Fc␥RIIB bear a single ITIM that, when tyrosyl-phosphorylated, recruits selectively the SH2 domain-bearing inositol-5-phosphatase SHIP (14) . We found recently that Fc␥RIIB are also capable of inhibiting RTK-dependent cell proliferation (15) . This finding opened the possibility that it might be a general property of ITIM-bearing molecules to regulate negatively not only ITAM-dependent cell activation but also RTK-mediated cell proliferation. If so, one could hypothesize that SIRP␣ might inhibit ITAM-dependent cell activation.
By contrast with KIRs whose expression is restricted to NK cells and T cells (11) , SIRP␣ were found to be expressed by all human tissues examined, including hematopoietic cells (3) , by * This work was supported by the INSERM, the Association pour la Recherche sur le Cancer, and the Institut Curie. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. neural and myeloid cells in rats (16) , and by myeloid cells, especially macrophages, but not lymphoid cells in mice (17) . Hematopoietic cells also express ITAM-bearing receptors. Thus, myeloid cells express ITAM-bearing receptors for the Fc portion of immunoglobulins (FcR) (18, 19) . These comprise high affinity IgE receptors (Fc⑀RI) (20) , high affinity IgG receptors (Fc␥RI) (21) , high affinity IgA receptors (Fc␣RI) (22) , and low affinity IgG receptors (Fc␥RIIIA) (23) , which all share the ITAM-bearing signal transduction subunit FcR␥ (18) . They also include the human-restricted, single chain, low affinity IgG receptors Fc␥RIIA/C that bear one ITAM in their own IC domain (18) . If they could interfere with ITAM-dependent cell activation, SIRP␣ would negatively regulate not only the growth but also the many biological functions of hematopoietic cells triggered by Fc receptors.
To investigate the hypothesis that SIRP␣ might negatively regulate cell activation induced by ITAM-bearing receptors, we constructed an experimental model in mast cells. Mast cells were chosen as an assay system because we found SIRP␣ transcripts in human mast cells. We report here that, when coaggregated with Fc⑀RI, a chimeric molecule whose IC domain was that of human SIRP␣ could inhibit IgE-induced mediator release and cytokine secretion by mast cells. The experimental model used made possible the biochemical analysis of intracellular events associated with inhibition. Inhibition was correlated with the tyrosyl phosphorylation of the SIRP␣ chimera, with the recruitment of SHP-1 and SHP-2 by the phosphorylated chimera, with a decreased phosphorylation of Fc⑀RI ITAMs, with attenuated Ca 2ϩ responses, and with an abolition of MAP kinase activation.
EXPERIMENTAL PROCEDURES
cDNA Constructs--cDNA sequences encoding the transmembrane (TM) and IC domains of SIRP␣ and of a human KIR were amplified from the human melanoma cell line HT-144 (from the ATCC) and from the p58.183 KIR cDNA (24) by RT-PCR and PCR, respectively, with the following oligonucleotide primers: for SIRP␣, sense, 5Ј-TCTAAGGTAC-CAAACATCTATATTGTGGTG-3Ј, and antisense, 5Ј-AGCAAACCGAG-CTCCCATTCACTTCCTCGGGACCTG-3Ј; for KIR, sense, 5Ј-CCCA-GAC AGGTACCTGTTCTGATTGGGACC-3Ј, and antisense, 5Ј-CTGA-CTGTGGAGCTCATGGGCAGG-3Ј. KpnI (GGTACC) and SacI (GAGC-TC) sites are in boldface. PCR products were inserted into an expression cassette under the control of the SR␣ promoter in pBR322 (25) , containing a resistance gene to neomycin (NT-neo) and containing the extracellular domain of Fc␥RIIB.
Cells-The human basophil-like KU812 (26) , the human mast cells HMC-1 (27) , and the rat mast cells RBL-2H3 (28) were cultured in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum, 100 IU/ml penicillin, 100 g/ml streptomycin, and 2 mM Lglutamine. Culture reagents were from Life Technologies, Inc. Human normal mast cells, obtained by culture of cord blood mononuclear cells as described (29) , were kindly donated by Dr. M. Arock (Faculté de Pharmacie, Paris, France). More than 99% cells were mast cells as judged by morphology, the presence of metachromatic granules, and positivity for tryptase. cDNAs encoding Fc␥RIIB-SIRP␣ and Fc␥RIIB-KIR were stably transfected in RBL-2H3 cells; transfectants were selected with 2.5 mg/ml G418 (Life Technologies, Inc.) and cloned as described (30) .
Antibodies-The mouse IgE anti-DNP mAb 2682-I (31) was used as culture supernatant. IgG and F(abЈ)2 fragments of the rat anti-mouse Fc␥RIIB 2.4G2 mAb (32) were obtained as described (30) . Rabbit antimouse Fc␥RIIB were raised by Dr. C. Sautès (Institut Curie, Paris, France) against recombinant extracellular domains of Fc␥RIIB. Mouse mAb anti-FcR␤ were purified with protein G-Sepharose (Amersham Pharmacia Biotech) from culture supernatants of the JRK hybridoma cells. Rabbit anti-FcR␥ antibodies and rabbit anti-mouse IgE antibodies were generous gifts of Dr. J.-P. Kinet (Beth Israel Hospital, Boston). IgG and F(abЈ)2 fragments of mouse anti-rat Ig (MAR) and FITCconjugated MAR F(abЈ)2 fragments (FITC-MAR F(abЈ)2) were from Jackson ImmunoResearch Laboratories (West Grove, PA). MAR F(abЈ)2 were trinitrophenylated with trinitrobenzene sulfonic acid (EastmanKodak Co.) and purified on Sephadex G-25 (Amersham Pharmacia Biotech). TNP 10 -MAR F(abЈ)2 were obtained. Horseradish peroxidase (HRP)-conjugated mouse mAb anti-phosphotyrosine (PY20) were purchased from Chemicon (Temecula, CA); mouse mAbs anti-SHP-1 and anti-SHP-2 were from Transduction Laboratories (Lexington, KY); mouse mAbs anti-Erk1/2 and anti-phospho-Erk1/2 were from New England Biolabs (Beverly, MA); HRP-conjugated polyclonal goat antimouse Ig (GAM) antibodies and polyclonal goat anti-rabbit Ig (GAR) antibodies were from Santa Cruz Biotechnology (Santa Cruz, CA).
Immunofluorescence-RBL transfectants were incubated for 1 h at 0°C with 10 g/ml 2.4G2 mAb in balanced salt solution containing 5% fetal calf serum. Cells were washed and stained by being incubated for 30 min at 0°C with 50 g/ml FITC-MAR F(abЈ)2. Fluorescence was analyzed by flow cytometry using a FACScalibur (Becton-Dickinson, Mountain View, CA).
RT-PCR Analysis of SIRP␣ Transcripts-RNA was extracted from 1 ϫ 10 7 KU812, HMC-1, and cord blood-derived human mast cells. cDNAs were prepared and used as templates to amplify sequences corresponding to the TM and IC domains of SIRP␣ using the two oligonucleotides SIRP␣ sense and antisense. Amplified fragments were sequenced using the same two oligonucleotides.
Serotonin Release-RBL transfectants, loaded with [ 3 H]serotonin (Amersham Pharmacia Biotech), were incubated for 1 h at 37°C with IgE anti-DNP and with 0 or 3 g/ml 2.4G2 F(abЈ)2, washed, and challenged for 30 min at 37°C with TNP-MAR F(abЈ)2 or with MAR F(abЈ2) and DNP-BSA. The percentage of [ 3 H]serotonin released was measured as described (30) .
TNF Secretion-RBL transfectants, incubated for 1 h at 37°C with IgE anti-DNP and 0 or 3 g/ml 2.4G2 F(abЈ)2, were challenged for 3 h at 37°C with 10 g/ml TNP-MAR F(abЈ)2. Cell-free supernatants were harvested and titrated for TNF␣ on L929 cells as described (33) .
Measurement of Intracellular Ca 2ϩ Concentration-RBL transfectants, previously sensitized with IgE anti-DNP and incubated with or without 2.4G2 F(abЈ)2, were loaded with 5 mM Fluo-3-AM in the presence of 0.2% Pluronic F-127 (Molecular Probes, Eugene, OR) for 30 min at room temperature. Cells were resuspended in medium in which calcium had been buffered to 60 nM (equivalent to the intracellular Ca 2ϩ concentration in resting cells) with EGTA. One min later, they were challenged with TNP-MAR F(abЈ)2 for 100 s, after which the extracellular Ca 2ϩ concentration was raised to 1.3 mM with CaCl 2 . Intracellular free Ca 2ϩ concentration was monitored by flow cytometry with a FACScalibur using the software FCS assistant 1.
2.9␤ (Becton Dickinson).
Immunoprecipitation and Western Blot Analysis-RBL transfectants were incubated with IgE anti-DNP and 0 or 3 g/ml 2.4G2 F(abЈ)2, washed, and challenged for various periods of time at 37°C with 10 g/ml TNP-MAR F(abЈ)2. Aliquots of 3 ϫ 10 7 cells were lysed for 10 min at 0°C. For immunoprecipitation of Fc␥RIIB, lysis buffer contained 10 mM Tris, pH 7.4, 150 mM NaCl, 1% Nonidet P-40, 1 mM Na 3 VO 4 , 5 mM NaF, 5 mM sodium pyrophosphate, 0.4 mM EDTA, 10 g/ml aprotinin, 10 g/ml leupeptin, 10 g/ml pepstatin, and 1 mM phenylmethylsulfonyl fluoride. For immunoprecipitation of Fc⑀RI, lysis buffer contained 50 mM Tris, pH 8.0, 1% Nonidet P-40, 1 mM Na 3 VO 4 , 20 mM EDTA, 10 g/ml aprotinin, 10 g/ml leupeptin, and 1 mM phenylmethylsulfonyl fluoride. Lysates were centrifuged at 12,000 rpm for 10 min at 4°C, and supernatants were incubated with immunoadsorbents for 1 h at 4°C. Protein G-Sepharose or 2.4G2 coupled to protein G-Sepharose was used to precipitate Fc␥RIIB from cells preincubated with 2.4G2 or not, respectively. Anti-mouse IgE antibodies coupled to protein A-Sepharose (Sigma) were used to precipitate Fc⑀RI from cells sensitized with mouse IgE. Immunoprecipitates were fractionated by SDS-PAGE and transferred onto Immobilon-P membranes (Millipore, Bedford, MA). Membranes were saturated either with 5% BSA (Sigma) or with 5% skimmed milk (Régilait, Saint-Martin-Belle-Roche, France) and Western-blotted with HRP-conjugated anti-phosphotyrosine antibodies or with rabbit anti-Fc␥RIIB, mouse anti-SHP-1, mouse anti-SHP-2, mouse anti-FcR␤, or rabbit anti-FcR␥ antibodies, followed by HRP-conjugated GAR or GAM. Anti-SHP-2 antibodies detected two species of SHP-2. Anti-SHP-1 and anti-SHP-2 antibodies recognized specifically SHP-1 and SHP-2, respectively. HRP-conjugated antibodies were detected using an enhanced chemiluminescence (ECL) kit (Amersham Pharmacia Biotech). When blotted sequentially with different antibodies, filters were stripped following revelation by being incubated for 30 min at 50°C in buffer containing 62.5 mM Tris, pH 6.7, 100 mM ␤-mercaptoethanol, and 2% SDS.
Western Blot Analysis of MAP Kinases-RBL transfectants were incubated for 1 h at 37°C with IgE anti-DNP and with 0 or 3 g/ml 2.4G2 F(abЈ)2, washed, and challenged with 10 g/ml TNP-MAR F(abЈ)2. Equal volumes of cell lysates, obtained as described for immunoprecipitation of Fc␥RIIB, were fractionated by SDS-PAGE, transferred onto Immobilon-P membranes, and blotted with anti-phospho-Erk1/2 or with anti-Erk1/2 antibodies, followed by HRP-conjugated GAR. HRP-conjugated antibodies were detected using the ECL kit.
RESULTS
Human Mast Cells Express SIRP␣-We investigated first the presence of SIRP␣ transcripts in RNA from human mast cells by RT-PCR using oligonucleotide primers that could amplify a 435-base pair long fragment corresponding to the TM and IC domains of human SIRP␣. A single PCR product having the expected size was amplified from cDNAs from the human mast cell line HMC-1 and from cord blood-derived human mast cells but not from the basophil-like cell line KU812 (Fig. 1A) . PCR products amplified from HMC-1 and from cord bloodderived mast cells were sequenced. They had the same nucleotide sequence as cDNA encoding the TM and IC domains of human SIRP␣ (3) .
A SIRP␣ Chimera Inhibits IgE-induced Mast Cell Activation When Coligated with Fc⑀RI-In order to examine whether SIRP␣ could inhibit IgE-induced mast cell activation, we constructed a cDNA encoding a chimeric molecule having the extracellular domain of murine Fc␥RIIB and the TM and IC domains of human SIRP␣ (Fc␥RIIB-SIRP␣). As a positive control, a cDNA encoding a chimeric molecule having the extracellular domain of murine Fc␥RIIB and the TM and IC domains of a human KIR (Fc␥RIIB-KIR) was also constructed (Fig. 1B) . Chimeric cDNAs were stably transfected in the rat mast cells RBL-2H3, which constitutively express Fc⑀RI. Clones of transfectants expressing comparable amounts of Fc␥RIIB-SIRP␣ or Fc␥RIIB-KIR (Fig. 1C) and, as negative controls, clones expressing tail-less Fc␥RIIB (Fc␥RIIB(IC1)) (30, 33) were used for experiments. Several clones expressing each molecule gave comparable results.
Fc␥RIIB-SIRP␣, Fc␥RIIB-KIR, or Fc␥RIIB(IC1) were coaggregated with Fc⑀RI in RBL transfectants sensitized with mouse IgE anti-DNP, incubated with F(abЈ)2 fragments of the rat anti-mouse Fc␥RIIB mAb 2.4G2, and challenged with TNP-MAR F(abЈ)2 as described previously (34) . Serotonin release induced under these conditions was compared with serotonin release induced by aggregating Fc⑀RI with TNP-MAR F(abЈ)2 in the same three transfectants sensitized with mouse IgE anti-DNP but not incubated with 2.4G2 F(abЈ)2. When coaggregated with Fc⑀RI, Fc␥RIIB-SIRP␣ inhibited serotonin release as efficiently as Fc␥RIIB-KIR, but not Fc␥RIIB(IC1) (Fig. 2A) .
To determine the conditions required for Fc␥RIIB-SIRP␣ to inhibit serotonin release, transfectants expressing Fc␥RIIB-SIRP␣ were sensitized with mouse IgE anti-DNP and incubated with 2.4G2 F(abЈ)2. Fc⑀RI and Fc␥RIIB-SIRP␣ were then either coaggregated by TNP-MAR F(abЈ)2 as above or aggregated simultaneously, but independently, by DNP-BSA and MAR F(abЈ)2, respectively. Cells sensitized with IgE but not incubated with 2.4G2 F(abЈ)2 served as positive controls. Serotonin release was inhibited when Fc⑀RI and Fc␥RIIB-SIRP␣ were coaggregated by TNP-MAR F(abЈ)2 but not when they were simultaneously aggregated by DNP-BSA and MAR F(abЈ)2 (Fig. 2B) .
To determine whether Fc␥RIIB-SIRP␣ could inhibit an IgEinduced secretion of cytokine, Fc⑀RI were either aggregated or coaggregated with Fc␥RIIB-SIRP␣ in transfectants expressing Fc␥RIIB-SIRP␣, using the same ligands as above, and the amount of TNF␣ released in culture supernatants during the following 3 h was titrated using a bioassay. When coaggregated with Fc⑀RI, Fc␥RIIB-SIRP␣ inhibited about 90% of the TNF␣ secretion (Fig. 2C) .
The SIRP␣ Chimera Becomes Tyrosyl-phosphorylated upon Coligation with Fc⑀RI and Recruits Protein Tyrosine Phosphatases-We examined next the phosphorylation of Fc␥RIIB-SIRP␣ when coaggregated with Fc⑀RI or not. Fc␥RIIB-SIRP␣ was immunoprecipitated from transfectants expressing Fc␥RIIB-SIRP␣ that had been incubated with medium alone, IgE anti-DNP and/or 2.4G2 F(abЈ)2, and challenged with or without TNP-MAR F(abЈ)2 for 3 min at 37°C. Western blot analysis with anti-phosphotyrosine antibodies showed that the basal phosphorylation of the chimera slightly increased when Fc␥RIIB-SIRP␣ was aggregated but not when Fc⑀RI were aggregated. It increased dramatically when Fc␥RIIB-SIRP␣ was coaggregated with Fc⑀RI (Fig. 3A) . When Fc␥RIIB-SIRP␣ was coaggregated with Fc⑀RI for various periods, its phosphorylation was apparent at 1 min, maximum between 3 and 10 min, and still visible at 30 min (Fig. 3B ). When coaggregated with Fc⑀RI, tail-less Fc␥RIIB failed to be phosphorylated (data not shown). Four tyrosine residues are present in the IC domain of SIRP␣, which are each constitutive of an ITIM-like motif.
To identify SH2 domain-bearing phosphatases possibly recruited in vivo by Fc␥RIIB-SIRP␣, the SIRP␣ chimera was immunoprecipitated after it had or had not been coaggregated with Fc⑀RI, and phosphatases coprecipitated with Fc␥RIIB-SIRP␣ were identified by Western blotting. Some SHP-2 coprecipitated with weakly phosphorylated Fc␥RIIB-SIRP␣ in resting cells, and high amounts of SHP-2 coprecipitated with Fc␥RIIB-SIRP␣ that became heavily phosphorylated upon coaggregation with Fc⑀RI. SHP-1 was coprecipitated with Fc␥RIIB-SIRP␣ following coaggregation of the chimera with Fc⑀RI only. Under the same conditions, Fc␥RIIB-KIR, which was also phosphorylated upon coaggregation with Fc⑀RI, recruited similar amounts of SHP-1 as Fc␥RIIB-SIRP␣ but much less SHP-2. SHIP was recruited neither by Fc␥RIIB-SIRP␣ nor by Fc␥RIIB-KIR (Fig. 3C) .
The SIRP␣ Chimera Blocks Signal Transduction by Fc⑀RI-An early step in IgE-induced signaling in mast cells is the tyrosyl phosphorylation of Fc⑀RI ITAMs (35) which enables the recruitment of SH2 domain-bearing cytoplasmic kinases, leading to an increased intracellular Ca 2ϩ concentration, and adapter molecules that connect phosphorylated receptors with the Ras pathway, leading to the transcription of cytokine genes. In RBL cells, Fc⑀RI are associated with two ITAMbearing subunits, FcR␤ and FcR␥ (20) .
The phosphorylation of Fc⑀RI ITAMs was examined by Western blot analysis with anti-phosphotyrosine antibodies in RBL transfectants sensitized with IgE anti-DNP, after Fc⑀RI were aggregated or coaggregated with the SIRP␣ chimera for 1, 3, or 10 min at 37°C and immunoprecipitated with anti-IgE antibodies. FcR␤ and FcR␥ were identified by Western blot analysis of the same filter with corresponding specific antibodies. The phosphorylation of both FcR␤ and FcR␥ induced upon Fc⑀RI aggregation was decreased upon coaggregation of Fc⑀RI with the SIRP␣ chimera (Fig. 4A) . Ca 2ϩ responses were monitored in RBL transfectants following Fc⑀RI aggregation or following the coaggregation of Fc⑀RI with the SIRP␣ chimera and, as a positive control, with the KIR chimera, under conditions that permitted us to measure the mobilization of intracellular Ca 2ϩ and the influx of extracellular Ca 2ϩ separately. Fc␥RIIB-SIRP␣ and Fc␥RIIB-KIR similarly reduced both the intracellular Ca 2ϩ mobilization and the extracellular Ca 2ϩ influx (Fig. 4B ). The activation of the Ras pathway was assessed by examining the phosphorylation of the MAP kinases Erk1 and Erk2. When coaggregated with Fc⑀RI, both Fc␥RIIB-SIRP␣ and Fc␥RIIB-KIR abolished IgE-induced Erk1/2 phosphorylation induced by aggregating Fc⑀RI (Fig. 4C ). DISCUSSION SIRP␣ were described as negative regulators of growth factor-induced, RTK-mediated cell proliferation (3). RTKs transphosphorylate each other when dimerized by growth factors (36) . They induce cells to enter the cell cycle and to divide. ITAM-bearing receptors have no intrinsic protein kinase activity, and they do not induce cells to proliferate. When aggregated by multivalent ligands, they are phosphorylated by Src family protein tyrosine kinases, and phosphorylated ITAMs serve as docking sites for cytoplasmic SH2 domain-bearing protein tyrosine kinases and adapter molecules that lead to cell activation (37). Although both early and late signals delivered by RTKs and ITAM-bearing receptors are different, these two types of receptors utilize common intracellular effectors such as phospholipase C-␥, phosphatidylinositol 3-kinase, and molecules of the Ras/MAP kinase pathway (37, 38). We found SIRP␣ transcripts in human mast cells, and we investigated the effects of a SIRP␣ chimera on the secretion of inflammatory mediators triggered by Fc⑀RI, a typical ITAM-bearing Fc receptor, in the rat mast cell line RBL-2H3. We provide here the first evidence that SIRP␣ can behave as ITIM-bearing molecules that negatively regulate ITAM-dependent cell activation, and we document the mechanism of inhibition by SIRP␣.
The experimental model used to demonstrate the inhibitory properties of SIRP␣ was validated by our finding that human mast cells contain SIRP␣ transcripts. This conclusion could be drawn from results obtained with both cord blood-derived human mast cells and with the human mastocytoma cells HMC-1. Cord blood-derived mast cells present the advantage of being normal, non-transformed cells but have the disadvantage of being potentially contaminated by (less than 1%) other cells, possibly including macrophages that express high levels of SIRPs. HMC-1 cells maintained in culture for years have the disadvantage of being transformed cells, but they have the advantage of excluding any cell contamination. The combined results obtained in the two cell types make it reasonable to conclude that human mast cells do express the SIRP␣ gene, and although the expression of SIRP␣ proteins was not formally demonstrated here, they justify that mast cell secretory responses were chosen as readouts to assess the ability of SIRP␣ to control cell activation.
The overexpression of SIRP␣ was reported to be sufficient to inhibit epidermal growth factor-, platelet-derived growth factor-, or insulin-induced cell proliferation in NIH-3T3 fibroblasts and ligand-independent proliferation of the same cells infected by a retrovirus carrying an oncogenic form of RTK (3). SIRP␣ are therefore likely to be constitutively associated with RTKs, and indeed, BIT coprecipitated with CSF-1R in a macrophage cell line (39) . By contrast, the overexpression of the Fc␥RIIB-SIRP␣ chimera in RBL-2H3 cells affected neither the growth of transfectants (data not shown) nor IgE-induced responses. Mediator release was inhibited when and only when Fc⑀RI and Fc␥RIIB-SIRP␣ were coaggregated by the same extracellular ligand. A possible explanation for the different requirements for SIRP␣ to inhibit RTK-dependent cell proliferation and for Fc␥RIIB-SIRP␣ to inhibit Fc⑀RI-dependent cell activation might be that SIRP␣ constitutively associate with RTKs (and possibly with Fc⑀RI) via their extracellular domains which were removed in the Fc␥RIIB-SIRP␣ chimera. Specific conditions under which Fc⑀RI and SIRP␣ could be coligated, if not constitutively associated, on mast cells remain to be determined, and it was not an aim of this investigation to address that issue. Our work indicates, however, that a previously undemonstrated negative regulation may operate in hematopoietic cells that coexpress SIRP␣ and ITAM-bearing receptors, provided the two receptors are maintained close to each other, either constitutively or inducibly by common extracellular ligands. One SIRP member, the neuronal adhesion molecule P84, was recently assigned an extracellular ligand. The integrin-associated protein CD47 was indeed found to bind to P84, and both molecules are colocalized in synapse-rich structures of the cerebellum and the retina where their interactions were proposed to control synaptic functions (5) . Whether CD47 is also a ligand for other SIRP family members and/or whether other ligands bind to the polymorphic extracellular domains of SIRP␣ is unknown. CD47 is widely expressed on T cells (40) , on myeloid cells including neutrophils (41) and mast cells (42) , on epithelial cells (41), on spleen, liver and bone marrow stromal cells (43) , on neurones (5, 16) , and on red blood cells (44) .
The mechanism underlying the inhibitory properties of SIRPs is poorly understood. One reason is the constitutive association of RTKs with SIRPs that made it difficult to analyze the respective roles of interacting molecules. The experimental model used here enabled us to dissect various stages of the process and to get some insight in the mechanism of inhibition by SIRP␣. One consequence of the coaggregation of Fc⑀RI with Fc␥RIIB-SIRP␣ was a dramatic tyrosyl phosphorylation of the chimera. A faint basal phosphorylation of Fc␥RIIB-SIRP␣ was observed in resting cells. This phosphorylation slightly increased upon Fc␥RIIB-SIRP␣ aggregation, suggesting that low levels of protein tyrosine kinase may associate with the chimera in mast cells. It did not increase upon stimulation by IgE, confirming that Fc␥RIIB-SIRP␣ was not associated with Fc⑀RI. The increased phosphorylation of Fc␥RIIB-SIRP␣, when coaggregated with Fc⑀RI, is likely to depend on Src protein tyrosine kinases that are recruited by aggregated Fc⑀RI, as it was previously demonstrated for the tyrosyl phosphorylation of Fc␥RIIB (34) .
Phosphorylated Fc␥RIIB-SIRP␣ was found to recruit SH2 domain-bearing cytoplasmic protein tyrosine phosphatases. The respective roles of the four ITIM-like motifs in phosphatase recruitment is not known as no mutational analysis of the four tyrosine residues contained in the SIRP␣ IC domain has been made. Some SHP-2 coprecipitated with lightly phosphorylated Fc␥RIIB-SIRP␣ in resting cells and much greater amounts with heavily phosphorylated Fc␥RIIB-SIRP␣, following its coaggregation with Fc⑀RI. Significant amounts of SHP-1 also coprecipitated with the phosphorylated chimera. Association with SHP-2 was instrumental for the identification of SIRPs (1-3) . SHP-1 associated with SIRP␣ when overexpressed in fibroblasts (2) and with SHPS-1 (17) and BIT (39) in macrophages. Noticeably, comparable amounts of SHP-1 coprecipitated with Fc␥RIIB-SIRP␣ and with Fc␥RIIB-KIR, whereas much more SHP-2 coprecipitated with Fc␥RIIB-SIRP␣ than with Fc␥RIIB-KIR. This indicates that Fc␥RIIB-SIRP␣ preferentially recruited SHP-2, whereas Fc␥RIIB-KIR preferentially recruited SHP-1, when coligated with the same receptors in RBL cells. In apparent contradistinction with our observation, SHPS-1 was reported to associate preferentially with SHP-1 in a mouse macrophage cell line, when phosphorylated following treatment with an analog of pervanadate, and in resting mouse spleen cells (17) . Whether the discrepancy can be explained by differences in the cell types and/or the experimental conditions needs to be clarified.
We found that Fc␥RIIB-SIRP␣ turned off signals transduced by Fc⑀RI. The inhibition of serotonin release and of TNF␣ synthesis was correlated with attenuated Ca 2ϩ responses, affecting both the mobilization of intracellular Ca 2ϩ stores and the influx of extracellular Ca 2ϩ and with an abolition of the activation of Erk1/2, as assessed by their phosphorylation. Our data neither support nor exclude the possibility that inhibition directly affected Ca 2ϩ responses or the Ras pathway. The observed reduced phosphorylation of Fc⑀RI ITAMs, however, indicates that inhibition affected signaling events that stand upstream of these two responses. One likely explanation would be that the FcR␤ and FcR␥ ITAMs or, possibly, the Src protein tyrosine kinase which phosphorylates Fc⑀RI ITAMs, were the substrates of protein tyrosine phosphatases recruited by phosphorylated Fc␥RIIB-SIRP␣. This mechanism has been proposed to account for SHP-1-dependent inhibition of Fc␥RIIIA-mediated antibody-dependent cell-mediated cytotoxicity by KIRs (45) . Whether SHP-2 can have the same effect as SHP-1 is unclear. SHP-2 was indeed assigned both positive (46) and negative effects (13, 47) . One may notice that, apparently, Fc␥RIIB-SIRP␣ was not much more inhibitory than Fc␥RIIB-KIR, although comparable amounts of SHP-1 coprecipitated with the two chimeras but much more SHP-2 with the SIRP chimera. This makes the role of SHP-2 in inhibition unclear. One interesting possibility would be that SHP-1 and SHP-2 have different substrates that may not fulfill the same functions. It has been suggested that the inhibitory properties of receptors that recruit SHP-2 could result from the sequestration of that phosphatase, preventing it from exerting positive effects on activating receptors (16) . If so, inhibition by SIRP␣ might result from the combined dephosphorylation of ITAMs and kinases by SHP-1 and the retention of SHP-2. Under these conditions, when recruited by SIRP␣, SHP-1 and SHP-2 would act in concert, and their complementary effects might explain the deep inhibition of the biological responses observed. Whatever the respective roles of the two phosphatases, our work documents a reciprocal cross-talk between SIRP␣ and ITAMbearing receptors during inhibition of cell activation. The coaggregation of Fc␥RIIB-SIRP␣ with Fc⑀RI may indeed enable both Fc⑀RI to provide protein tyrosine kinases that could phosphorylate SIRP␣ ITIMs and Fc␥RIIB-SIRP␣ to provide protein tyrosine phosphatases that could dephosphorylate Fc⑀RI ITAMs and sequester phosphatases possibly required for cell activation.
Myeloid cells, such as macrophages and mast cells, coexpress not only ITAM-bearing FcR and SIRP␣ but also RTKs and Fc␥RIIB. We found recently that Fc␥RIIB, which were known to regulate negatively ITAM-dependent cell activation (8) , can also negatively regulate RTK-dependent cell proliferation and that inhibition is correlated with the recruitment of the SH2 domain-bearing inositol-5-phosphatase SHIP (15) . We show here that SIRP␣, which were known to regulate negatively RTK-dependent cell proliferation, can also negatively regulate ITAM-dependent cell activation and that inhibition is correlated with the recruitment of SHP-2 and SHP-1. It follows 1) that SIRP␣ bear typical ITIMs which endow these molecules with a wide array of previously unsuspected regulatory properties, and 2) that ITIMs can negatively regulate both cell activation and cell proliferation via the recruitment of either SHPs or SHIP. RTK-dependent cell proliferation and ITAM-dependent cell activation can therefore be negatively regulated, through common mechanisms, by the same receptors which may coordinately control the development and the functions of hematopoietic cells.
